Radiotherapy and Olaparib in COmbination for Carcinoma of the Oesophagus. A Phase I Trial.
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Olaparib (Primary)
- Indications Adenocarcinoma; Oesophageal cancer
- Focus Adverse reactions; Biomarker
- Acronyms ROCOCO
- 25 Feb 2016 Planned End Date changed from 1 Aug 2018 to 1 Sep 2016 as reported by United Kingdom Clinical Research Network.
- 02 Apr 2015 Accrual to date is 27% according to United Kingdom Clinical Research Network record.
- 11 Mar 2015 Accrual to date is 25% according to United Kingdom Clinical Research Network record.